Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed
to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with
doxorubicin alone in subjects with previously untreated, locally advanced or metastatic,
unresectable soft tissue sarcoma.